Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Income towards Common Stockholders: 2014-2025

Historic Net Income towards Common Stockholders for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$35.1 million.

  • Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders stood at -$35.1 million, which was up 65.20% from -$100.7 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders' 5-year high stood at -$14.0 million during Q3 2021, with a 5-year trough of -$100.7 million in Q2 2025.
  • Its 3-year average for Net Income towards Common Stockholders is -$66.4 million, with a median of -$66.9 million in 2023.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders in the last 5 years was 68.10% (2021), contrasted with its biggest fall of 179.16% (2021).
  • Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders (Quarterly) stood at -$28.9 million in 2021, then slumped by 58.17% to -$45.8 million in 2022, then crashed by 46.03% to -$66.9 million in 2023, then fell by 19.33% to -$79.8 million in 2024, then soared by 54.18% to -$35.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$35.1 million in Q3 2025, compared to -$100.7 million in Q2 2025 and -$86.9 million in Q1 2025.